Novel Drug Delivery Technologies For The Treatment Of Rheumatoid Arthritis

10.5580/7ce ◽  
2009 ◽  
Vol 5 (1) ◽  
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Delivery ◽  
Novel Drug

Novel Nano Carriers for the Treatment of Progressive Auto Immune Disease Rheumatoid Arthritis

2020 ◽  
Vol 26 ◽  
Author(s):  
Ritu Mishra ◽  
Swati Gupta
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Delivery ◽  
Autoimmune Disease ◽  
Drug Delivery Systems ◽  
Clinical Manifestations ◽  
Adaptive Immune Response ◽  
Delivery Systems ◽  
Current Therapy ◽  
Genetic And Environmental Factors ◽  
Novel Drug

Background: Rheumatoid arthritis (RA) is the most common occurring progressive, autoimmune disease, affecting 1% of the population and the ratio of affected women is three times as compared to men in most developing countries. Clinical manifestations of RA are the presence of anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF) in blood, tendered joints and soreness of the muscles. Some other factors which may lead to chronic inflammation are genetic and environmental factors as well as adaptive immune response. Several conventional drugs are available for the treatment of RA but have their own drawbacks which can be overcome by the use of novel drug delivery systems. : The objective of the present review is to focus on the molecular pathogenesis of the disease and its current conventional treatment with special reference to the role of novel drug delivery systems encapsulating anti rheumatic drugs and herbal drugs in passive and receptor mediated active targeting against RA. On reviewing the conventional and current therapeutics agains RA, we conclude that, although the current therapy for the treatment of RA is capable enough, yet more advances in the field of targeted drug delivery will sanguinely result in effective and appropriate treatment of this autoimmune disease.

scholarly journals CD44 receptor-targeted novel drug delivery strategies for rheumatoid arthritis therapy

2021 ◽  
Author(s):  
Srividya Gorantla ◽  
Ganesh Gorantla ◽  
Ranendra N. Saha ◽  
Gautam Singhvi
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Delivery ◽  
Cd44 Receptor ◽  
Delivery Strategies ◽  
Novel Drug

scholarly journals Novel Drug Delivery Systems for Rheumatoid Arthritis: An Approach to Better Patient Compliance

2019 ◽  
Vol 12 (1) ◽  
pp. 157-170 ◽  
Author(s):  
Sangeeta Mohanty ◽  
Sthitapragnya Panda ◽  
Aslesha Bhanja ◽  
Abhisek Pal ◽  
Si Sudam Chandra
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Human Life ◽  
Therapeutic Agents ◽  
Delivery Systems ◽  
Future Perspectives ◽  
Conventional Drug ◽  
Potential Applications ◽  
Novel Drug

Recent advances in science and technology radically changed the way we detect, treat and prevent different diseases in all aspects of human life. Rheumatoid arthritis (RA) is a chronic, systemic, progressive, autoimmune disease in which the body’s immune system whose major role is to protect the health by attacking foreign bacteria and viruses are mistakenly, attacking the joints resulting in thickened synovium, pannus formation, & destruction of bone, cartilage. Still now researchers are unable to know the exact cause of this disease. However, it is believed that genes and environmental factors play a role in development of RA. In this review, we discuss the Pathophysiology, predictors, & factors involved in pathogenesis of RA. We also discuss the Conventional therapeutic agents for Rheumatoid Arthritis. More importantly, we extensively discuss the emerging novel drug delivery systems (NDDS) like nanoparticles, dendrimers, micelles, microspheres, liposomes, and so on as these are the promising tools having successful applications in overcoming the limitations associated with conventional drug delivery systems. Although several NDDS have been used for various purposes, liposomes have been focused on due to its potential applications in RA diagnosis and therapy. In addition, we discuss the therapeutic effectiveness and challenges for RA by using these novel drug delivery systems. Finally, we conclude by discussing the future perspectives.

Novel drug delivery systems for NSAIDs in management of rheumatoid arthritis: An overview

2018 ◽  
Vol 106 ◽  
pp. 1011-1023 ◽  
Author(s):  
Sourav Thakur ◽  
Bushra Riyaz ◽  
Akshay Patil ◽  
Amanjot Kaur ◽  
Bhupinder Kapoor ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Novel Drug

Novel drug delivery approaches in treating pulmonary fibrosis

2018 ◽  
Vol 60 (4) ◽  
Author(s):  
Kamal Dua ◽  
Rajendra Awasthi ◽  
Jyotsana R. Madan ◽  
Dinesh K. Chellappan ◽  
Buchi N. Nalluri ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Pulmonary Fibrosis ◽  
Novel Drug

Development and Evaluation of Floating Pulsatile Drug Delivery System Using Meloxicam

2017 ◽  
Vol 7 (04) ◽  
Author(s):  
ShirishaG. Suddala ◽  
S. K. Sahoo ◽  
M. R. Yamsani
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Delivery ◽  
Drug Release ◽  
Drug Delivery System ◽  
Delivery System ◽  
Lag Time ◽  
Oral Dosage ◽  
Lag Phase ◽  
Pulsatile Drug Delivery

Objective: The objective of this research work was to develop and evaluate the floating– pulsatile drug delivery system (FPDDS) of meloxicam intended for Chrono pharmacotherapy of rheumatoid arthritis. Methods: The system consisting of drug containing core, coated with hydrophilic erodible polymer, which is responsible for a lag phase for pulsatile release, top cover buoyant layer was prepared with HPMC K4M and sodium bicarbonate, provides buoyancy to increase retention of the oral dosage form in the stomach. Meloxicam is a COX-2 inhibitor used to treat joint diseases such as osteoarthritis and rheumatoid arthritis. For rheumatoid arthritis Chrono pharmacotherapy has been recommended to ensure that the highest blood levels of the drug coincide with peak pain and stiffness. Result and discussion: The prepared tablets were characterized and found to exhibit satisfactory physico-chemical characteristics. Hence, the main objective of present work is to formulate FPDDS of meloxicam in order to achieve drug release after pre-determined lag phase. Developed formulations were evaluated for in vitro drug release studies, water uptake and erosion studies, floating behaviour and in vivo radiology studies. Results showed that a certain lag time before drug release which was due to the erosion of the hydrophilic erodible polymer. The lag time clearly depends on the type and amount of hydrophilic polymer which was applied on the inner cores. Floating time and floating lag time was controlled by quantity and composition of buoyant layer. In vivo radiology studies point out the capability of the system of longer residence time of the tablets in the gastric region and releasing the drug after a programmed lag time. Conclusion: The optimized formulation of the developed system provided a lag phase while showing the gastroretension followed by pulsatile drug release that would be beneficial for chronotherapy of rheumatoid arthritis and osteoarthritis.

A Review on Fast Dissolving Tablet

2017 ◽  
Vol 8 (03) ◽  
Author(s):  
Sagar T. Malsane ◽  
Smita S. Aher ◽  
R. B. Saudagar
Keyword(s):  
Drug Delivery ◽  
Patient Compliance ◽  
Research Area ◽  
Oral Route ◽  
Dosage Forms ◽  
The Novel ◽  
The Past ◽  
Orally Disintegrating Tablets ◽  
Novel Drug ◽  
Experience Difficulty

Oral route is presently the gold standard in the pharmaceutical industry where it is regarded as the safest, most economical and most convenient method of drug delivery resulting in highest patient compliance. Over the past three decades, orally disintegrating tablets (FDTs) have gained considerable attention due to patient compliance. Usually, elderly people experience difficulty in swallowing the conventional dosage forms like tablets, capsules, solutions and suspensions because of tremors of extremities and dysphagia. In some cases such as motion sickness, sudden episodes of allergic attack or coughing, and an unavailability of water, swallowing conventional tablets may be difficult. One such problem can be solved in the novel drug delivery system by formulating “Fast dissolving tablets” (FDTs) which disintegrates or dissolves rapidly without water within few seconds in the mouth due to the action of superdisintegrant or maximizing pore structure in the formulation. The review describes the various formulation aspects, superdisintegrants employed and technologies developed for FDTs, along with various excipients, evaluation tests, marketed formulation and drugs used in this research area.

Novel Topical Drug Delivery Approaches for the Management of Psoriasis

2020 ◽  
Vol 13 (5) ◽  
pp. 5062-5068
Author(s):  
Bhumika Kumar ◽  
Monika Targhotra ◽  
Rohan Aggarwal ◽  
Sahoo P.K
Keyword(s):  
Drug Delivery ◽  
Life Quality ◽  
Skin Area ◽  
Treatment Approaches ◽  
Treatment Regimens ◽  
Skin Cell ◽  
Conventional Drug ◽  
Severity Of The Disease ◽  
Novel Drug ◽  
Disease Location

Psoriasis is one of the most stern and persistent autoimmune disease which affects about 1-3% population around the globe.  It influences an individual’s life quality by hindering them physically, socially and emotionally. The hyperproliferation of keratinocytes leads to excessive growth of skin cell which causes scaling and formation of plaques. Psoriasis can be mild moderate or severe depending on the percentage of skin area affected. Based on severity of the disease, location and the type of psoriasis, the treatment approaches can vary. Treatment regimens for psoriasis include topical therapies, systemic therapies and phototherapy. Conventional drug delivery approaches face various disadvantages therefore a need for better novel drug delivery system is required. The review paper focuses at providing a broad aspect of psoriasis and the novel treatment approaches which can help in tackling the disease.  

Sign in / Sign up

Export Citation Format

Share Document